Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06119789

Precision Cancer Therapy in Rare Cancers

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers.

In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Rare Malignant Neoplasm

Age range

16 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Oslo University Hospital

Oslo, 0310, Norway

Location status: Recruiting

Location contact

Katarina Puco, MD

CONTACT

[email protected]

Åsa Öjlert, MD PhD

CONTACT

[email protected]

About this study

All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ECOG 0-2,
  • identified biomarker,
  • reasonable biochemistry

Exclusion criteria

  • ECOG 3-5
  • serious other diseases

Treatment and study plan

Imatinib

Drug

imatinib treatment based on molecular alterations

Trametinib

Drug

According to biomarkers

Dabrafenib

Drug

According to biomarkers

Primary outcomes

  1. Radiological response evaluation at 16 weeks of treatment

    Time frame: 16 weeks

    Standard radiological response evaluation, like RECIST criteria.

Secondary outcomes

  1. Molecular analyses predicting responses

    Time frame: 2 years

    Sequencing of tumor material and blood samples

Study contacts

Contact information is provided by the study sponsor or research team.

Kathinka Slørdahl, MD PhD

CONTACT

[email protected]

Åslaug Helland, MD PhD

CONTACT

[email protected]

+4795940863

Sponsors and collaborators

Lead sponsor

Oslo University Hospital

Other

Collaborators

  • Haukeland University Hospital
  • Helse Fonna
  • Helse Forde
  • Helse Nord-Trøndelag HF
  • Helse Stavanger HF
  • Møre og Romsdal Hospital Trust
  • Nordlandssykehuset HF
  • Sorlandet Hospital HF
  • StOlavs Hospital
  • Sykehuset Innlandet HF
  • Sykehuset Ostfold
  • The Hospital of Vestfold
  • University Hospital of North Norway

Registry information

Official study title

The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers

Acronym: MATRIX-Rare

Important dates

Study start
2025
Primary completion
2033
Study completion
2036
First posted
Nov 7, 2023
Registry last updated
Mar 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.